Get started

Nyse

Dominion Energy Inc. September 02, 2025.$D #DominionEnergy — Dominion Energy Inc. (NYSE:D) Insider Activity Report | Utilities | Utilities - Regulated Electric | USA | NYSE | September 02, 2025. Overview: This report evaluates the recent open-market purchase of Dominion Energy (D) shares by its Chair, President, and CEO on August 27, 2025. Dominion, a leading regulated utility with a focus on transitioning to clean energy, is well-positioned amid surging electricity demand from data centers and renewable initiatives. The insider activity, against a backdrop of solid Q2 earnings and strategic investments, suggests executive confidence in near-term value creation. This analysis is tailored for institutional investors seeking exposure to resilient utility plays with growth catalysts. 1. Insider Trading On Aug 27, 2025, Dominion’s boss Robert Blue (Chair, President & CEO) bought 4,331 shares @ $60.35. Ticket size: ~$250k. (SEC Form 4) www.sec.gov Not huge for a $50B utility, but it’s his first open-market buy since Mar ‘24. No insider sales on record. That’s a confidence move. 2. Fundamentals • Q2 EPS: $0.75 (beat by 8.7%). Revenues $3.5B (+3% vs est). • FY25 EPS guidance reaffirmed at $3.28–$3.52. • Dividend yield ~4.5% — not bad while you wait. • $50B capex plan (2025–2029) focused on data centers + renewables. • Offshore wind project facing cost bumps, but still on track. 3. Big Picture • Utilities usually move slow, but AI/data-center demand is a real tailwind. • Dominion already hooked up 15 centers (1,000 MW) in 2024, another 15 on deck this year. • SCC hearings Sept 2 on rate adjustments — could unlock recovery on those heavy investments. Charts: • (3W) Insider Trades: D Ownership: 4. Trade Setup Entry: $59.90–$60.35 (right around CEO’s buy). Targets: ➡️ Short-term: $72.00 ➡️ Mid-term: $79.00 ➡️ Long-term: $84.00 Takeaway CEO’s dipping into his own pocket right after an earnings beat + with data-center growth at his back? That’s not charity. That’s conviction. For me, $D looks like a buy/accumulate here with 20–40% upside over 6–12 months. Worst case you clip the dividend while waiting — not the worst seat in the house.
NYSE:DLong
by SergioRichi
DIS-Price is ranging but I'm ready to buy🕰 Monthly View Price is still trading inside the monthly swing range. Strong supply zone overhead near 140–160 where price has previously rejected. Current candles show rejection from monthly resistance but still holding above major support (≈82–85). Bigger picture: a break above the monthly supply could trigger continuation to 160–180. 📆 Weekly View Weekly structure shows a Head and Shoulders pattern completed, with a recent retest. Price currently pressing into resistance around 118–120. Break and hold above this zone would open a path to the 159.55 target level. Downside risk: failure here leads to deeper retracement back toward 85–90 support. 📅 Daily View Market remains in a ranging environment between ~82 and 145. Current move is testing resistance within this range (≈115–120). Two scenarios: Option 1: Break resistance → push into 135–140, eventually 159. Option 2: Reject resistance → swing lower back into demand zones (≈95–100 or even 85). ⏱ 8H View Price is coiling below weekly resistance. Short-term rejection possible before a larger breakout attempt. If bulls hold above local support, expect impulse push toward 130+. 🎯 Bias & Trade Plan Bias: Neutral–Bullish (range breakout play) Entry Zone: Look for demand confirmations around 100–105 or 95–100. Upside Targets: Short-term → 130–135 Mid-term → 159.55 (key supply) Invalidation: Break below 82 (monthly strong support). ⚠️ Risk Note DIS is consolidating long-term. Best plays are at range extremes (buy support or sell resistance). Wait for breakout confirmation before loading into swing positions.
NYSE:DISLong
by jamesibartram
AMRZ — Amrize Ltd = August 27, 2025.NYSE:AMRZ #AMRZ — Amrize Ltd (NYSE:AMRZ) | Basic Materials | Building Materials | Switzerland | NYSE | August 27, 2025. Executive Summary Amrize Ltd (NYSE: AMRZ), a Swiss-based building materials company focused on the North American market, demonstrates strong insider confidence through repeated purchases by Chief Technology Officer Roald Brouwer. In August 2025, Brouwer acquired a total of 5,000 shares across multiple transactions: 2,000 shares on August 27 at $51.88 per share (value $103,760), 1,000 shares on August 12 at $46.84 (value $46,840), 1,000 shares on August 11 at $48.08 (value $48,078), and 1,000 shares on August 8 at $46.25 (value $46,250). These buys, disclosed via SEC Form 4, increased his holdings to 5,000 shares, signaling optimism amid stable Q2 2025 results and strategic partnerships. Technical analysis reveals a bullish reversal setup on the daily chart, with the stock breaking out from consolidation near $46-48 to $51.96, supported by rising volume and neutral RSI, indicating high probability (75-85%) of continued upside. Q2 2025 financials showed stable revenue at $3.22 billion and net income of $428 million ($0.78 EPS), with cost-saving initiatives expected to boost margins from H2 2025. Key news includes a partnership with Meta announced on August 13, 2025, driving a 6.07% intraday gain, and analyst upgrades with targets implying 17-21% upside. Replicating Brouwer's average entry at ~$48.26 offers substantial reward potential of 20-50% over 3-6 months, targeting $58-$72. With a Zacks-style Buy rating and institutional backing, we view AMRZ as a high-conviction long in the materials sector, recommending 2-4% portfolio allocation for growth-oriented strategies. Company Profile Amrize Ltd (AMRZ) is a Zug, Switzerland-based company specializing in building materials, with operations exclusively focused on the North American market. Incorporated in 2023, Amrize earns revenue primarily from the sale of cement, aggregates, ready-mixed concrete, and related products, serving construction, infrastructure, and residential sectors. The firm positions itself as a key player in sustainable building solutions, leveraging advanced technology for efficient production and distribution. Key financial metrics as of August 27, 2025: • Market Capitalization: $28.72 billion • Enterprise Value: $36.98 billion (approx.) • Earnings Date: 11/5/2025 • Put Call Ration: 9.36 • Put Volume: 440.00 • Call Volume: 47.00 • Insider Ownership: 10.61% • Institutional Ownership: 31.55% Amrize's strategy emphasizes operational efficiency, with expected annual cost savings of $200-300 million starting in 2026 from ongoing initiatives. The company's strong balance sheet supports M&A and organic growth in a $200 billion North American building materials market. Charts: • (1D) • (30 Min) Roald Brouwer (Insider), Insider Trades: AMRZ Ownership: SEC From 4: www.sec.gov ➖➖➖ Insider Activity Analysis Insider buying serves as a robust indicator of undervaluation, especially when clustered and executed by technical leaders like the CTO, who have deep insights into innovation pipelines. For AMRZ, CTO Roald Brouwer's August 2025 purchases total 5,000 shares at an average price of $48.26, representing over $244,928 in value. This activity follows a pattern of executive accumulation, including President Jaime Hill's buys of 500 shares on August 22 at $49.59 and 4,000 shares on August 15 at $52.00. No significant sales were reported in Q3 2025, resulting in net insider buying of approximately $500,000 year-to-date. Brouwer's transactions, filed promptly via SEC Form 4, align with post-earnings stability and suggest confidence in near-term catalysts. Historically, such insider clusters in materials stocks correlate with 15-30% outperformance over six months, particularly in cyclical sectors like construction. ➖➖➖ Technical Analysis As a hedge fund trader, the daily chart for AMRZ presents a high-conviction bullish setup with an 80% probability of near-term gains, driven by a breakout from a multi-week consolidation base. Since bottoming at ~$46 in early August 2025, the stock has formed higher lows, culminating in a sharp volume-driven spike to $52.24 on August 27, closing at $51.96 (up 0.00% intraday but +12% month-to-date). This move breaches descending trendline resistance, confirmed by a bullish engulfing candle and 1.81 million share volume—50% above the 20-day average—indicating institutional accumulation. Key indicators affirm strength: • Moving Averages: Price above the 20-day SMA ($50.21) for the first time since July, with the 50-day SMA ($52.05) as next target; a golden cross (50-day over 200-day) is imminent if momentum holds. • Relative Strength Index (RSI, 14-period): At 56.61 (neutral-bullish), up from 40 in mid-August, with no overbought signals (>70) to suggest pullback risk. • Volume Analysis: OBV (On-Balance Volume) trending higher, supporting price advance; recent spikes align with insider buys and news. • Support and Resistance: Immediate support at $50.00 (psychological/20-day SMA) and $48.00 (prior breakout level). Resistance at $52.50 (recent high) and $55.00 (52-week high). • Chart Patterns: Ascending triangle breakout targets a measured move to $58 (adding pattern height to breakout point), with Fibonacci extensions from the August low pointing to $60 (161.8%). This configuration mirrors classic hedge fund plays in cyclical stocks, where insider-aligned breakouts yield 20-40% returns in 1-3 months amid sector tailwinds. ➖➖➖ Fundamental and News Analysis Fundamentally, AMRZ's Q2 2025 results (released August 6) underscore resilience: revenue held steady at $3.22 billion (vs. $3.243 billion YoY), with net income at $428 million ($0.78 EPS, down from $473 million but beating estimates by 5%). EBITDA margins improved to 21.5% via cost controls, positioning the company for $200-300 million in annual savings from H2 2025. Analysts project FY2025 EPS at $3.25 (forward P/E 16.0) and revenue growth of 5-7% in 2026, driven by North American infrastructure demand. Fresh news catalyzes upside: ➖ August 27, 2025: CTO Brouwer's 2,000-share buy reinforces post-earnings momentum. ➖ August 13, 2025: Strategic partnership with Meta for AI-optimized supply chain solutions, boosting stock 6.07% and highlighting tech integration in materials. ➖ August 6, 2025: Q2 earnings call emphasized "position of strength," with management guiding for margin expansion amid stable demand. Broader Context: U.S. infrastructure bill tailwinds and European supply chain shifts favor AMRZ's North American focus; analyst consensus (e.g., JP Morgan Price target at $60, Bernstein Price target at $62) implies 17-21% upside. Sentiment on X is bullish around the Meta deal, with posts noting potential for efficiency gains. Short interest low at 1.2%, reducing squeeze risk but affirming stability. ➖➖➖ Investment Thesis and Forecast Insider accumulation at undervalued levels, combined with technical breakout and earnings resilience, positions AMRZ for outperformance in materials. Entry Price : $51.96 Potential Growth : 11-38% over 3-6 months, leveraging infrastructure demand and tech partnerships. Exit Targets: ➖ Conservative (Target 1): $58.00 (11.62% profit) ➖ Moderate (Target 2): $65.00 (25.10% profit) ➖ Aggressive (Target 3): $72.00 (38.57% profit) Recommendation : Strong Buy; allocate 2-4% for cyclical exposure in diversified portfolios. Disclaimer: This report is for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.
NYSE:AMRZLong
by SergioRichi
1
BFLY — Butterfly Network Inc. | August 27, 2025.NYSE:BFLY #BFLY — Butterfly Network Inc. (NYSE:BFLY) | Healthcare | Medical Devices | USA | NYSE | August 27, 2025. Executive Summary Butterfly Network Inc. (NYSE: BFLY), an innovative medical device company specializing in portable ultrasound technology, exhibits strong insider conviction through a recent purchase by Chief Business Officer Steve Cashman. On August 25, 2025, Cashman acquired 50,000 shares of Class A common stock at an average price of $1.64 per share, totaling $81,953 in value. This transaction, disclosed via SEC Form 4 on August 27, 2025, increased his direct holdings to 2,324,474 shares, representing a significant vote of confidence in the company's trajectory amid a challenging market environment. Technical indicators on the daily chart suggest a potential reversal from a prolonged downtrend, with the stock trading at oversold levels and showing early signs of stabilization near $1.57. Q2 2025 financials reported record revenue of $23.4 million (up 9% YoY), with net losses narrowing by 59%, bolstered by cost efficiencies and AI-driven product enhancements. Recent news highlights include a new distribution agreement with Clipper Distributing for veterinary applications (August 25, 2025) and participation in an AI-assisted POCUS research project for tuberculosis detection in Sub-Saharan Africa (August 19, 2025), underscoring growth in both human and animal health sectors. Replicating Cashman's buy at approximately $1.64 presents a high probability of profitability, with estimated upside potential of 50-200% over the next 6-12 months, targeting $2.50-$5.00. This is supported by Zacks Rank #2 (Buy) and analyst projections of 124-127% upside. We recommend a speculative long position with tight risk controls, allocating 1-2% of portfolio capital, given the asymmetric reward in the medtech space. Company Profile Butterfly Network Inc. (BFLY) is a Burlington, Massachusetts-based healthcare technology firm revolutionizing medical imaging through its handheld, AI-enabled ultrasound devices. The flagship product, the Butterfly iQ+ probe, integrates semiconductor technology with cloud-based software to provide affordable, portable point-of-care ultrasound (POCUS) solutions for clinicians worldwide. The company operates in the medical devices sector, targeting applications in cardiology, emergency medicine, and now veterinary care, with a focus on democratizing access to diagnostic imaging in underserved markets. Key financial metrics as of August 27, 2025: • Market Capitalization: $395.24 million • Enterprise Value: $268.75 million (approx.) • Price-to-Sales (TTM): 4.52 • Price-to-Book (MRQ): 1.69 BFLY's business model emphasizes subscription-based software and AI integrations, with recent expansions into veterinary and global health initiatives driving revenue diversification. The company reported a cash position enabling continued R&D investment, though profitability remains elusive amid scaling efforts. Charts: • (1D) • (5D) Steve Cashman (Insider), Insider Trades: BFLY Ownership: SEC From 4: www.sec.gov Insider Activity Analysis Insider purchases, particularly by C-suite executives, often signal undervaluation and internal optimism about future catalysts. For BFLY, CBO Steve Cashman's August 25, 2025, acquisition of 50,000 shares at $1.64 per share is noteworthy, as it occurs near 52-week lows and follows a pattern of net insider buying. Post-transaction, Cashman's direct ownership stands at 2,324,474 shares, reflecting a substantial personal stake aligned with shareholders. Broader insider trends show mixed activity: While insiders sold approximately $1.6 million in stock over the past year, recent months have tilted toward buys, including this transaction. No other major executive purchases were reported in August 2025, but the absence of sales post-Q2 earnings suggests stabilizing sentiment. This aligns with historical data where clustered buys in medtech firms precede 20-50% rebounds within quarters, especially when tied to product launches or partnerships. Technical Analysis The daily chart for BFLY depicts a pronounced downtrend since peaking above $5.00 in early 2025, with the price eroding over 60% to current levels around $1.57 amid broader healthcare sector pressures. Price action forms a descending wedge pattern, characterized by lower highs and lows, trading below key simple moving averages (20-day SMA at $1.74, 50-day at $2.50, 200-day at $2.81), confirming bearish momentum. However, recent sessions exhibit green candles with modest volume spikes (e.g., 1.44M shares on August 27), hinting at accumulation. Key indicators bolster a high-probability reversal case: • Relative Strength Index (RSI, 14-period): At 49.65 on the primary chart (neutral) and 38.75 on the secondary (approaching oversold <30), signaling potential exhaustion without bearish divergence. • Volume Analysis: Average volume has risen 15% month-over-month, aligning with insider activity and news releases, suggesting institutional interest. • Support and Resistance: Immediate support at $1.50 (recent swing low) and $1.21 (52-week low). Resistance at $1.80 (near-term pivot), $2.50 (50-day SMA), and $3.00 (prior consolidation zone). • Chart Patterns: The wedge could resolve bullishly if price breaks above $1.80 on volume, targeting a measured move to $3.00+. Elliott Wave interpretation suggests completion of a five-wave decline, with the current level as a Wave 5 low, setting up for a corrective ABC rally. Overall , the setup offers a 70-80% chance of near-term profitability, as oversold conditions combined with insider buying often catalyze 50%+ gains in small-cap medtech stocks. Fundamental and News Analysis Fundamentally, BFLY delivered solid Q2 2025 results on August 1, 2025, with revenue reaching a record $23.4 million (9% YoY growth) and net loss reduced by 59% to an unspecified figure, driven by operational efficiencies and AI software adoption. Analysts project continued revenue expansion, with a Zacks Rank #2 (Buy) and consensus targets implying 124-127% upside. The company also announced a CFO transition effective August 1, 2025, to Heather Getz from Johnson & Johnson, bringing expertise in scaling medtech operations. Recent news reinforces momentum: ➖ August 25, 2025: Partnership with Clipper Distributing to expand Butterfly's ultrasound devices into veterinary markets, potentially unlocking new revenue streams in animal health. ➖ August 19, 2025: Joined a research project on AI-assisted POCUS for early tuberculosis detection in Sub-Saharan Africa, highlighting global health applications. ➖ August 1, 2025: Q2 earnings call emphasized Compass AI software launch for workflow efficiency, with management guiding for full-year revenue growth. Broader Context: The portable ultrasound market is forecasted to grow at 15% CAGR through 2030, benefiting BFLY's disruptive tech amid rising demand for point-of-care diagnostics. Social sentiment on X is positive around the Clipper partnership, with mentions of veterinary adoption and stock upside. No adverse events reported, though short interest remains elevated at 23.55% as of August 22, 2025. ➖➖➖ Investment Thesis and Forecast The insider buy at depressed valuations, coupled with technical bottoming and positive catalysts, positions BFLY for a rebound in the medtech sector. Replicating Cashman's entry at $1.64 yields the following scenario: Entry Price: $1.64 Potential Growth: 50-200% over 6-12 months, fueled by AI product launches and market expansions. Exit Targets: ➖ Conservative (Target 1): $2.50 (52% profit, +$0.86/share) – Exit at 50-day SMA or post-partnership revenue updates. ➖ Moderate (Target 2): $3.50 (113% profit, +$1.86/share) – Scale out 50% on RSI >70 or analyst upgrades. ➖ Aggressive (Target 3): $5.00 (205% profit, +$3.36/share) – Full exit on breakout above $4.00 or M&A speculation. This thesis assumes favorable macro conditions for healthcare tech; adjust for sector trends. Recommendation : Buy with conviction; target allocation 1-2% for high-conviction speculative basket. Disclaimer : This report is for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.
NYSE:BFLYLong
by SergioRichi
NYSE - Short | Disaster ImminentStocks continue to struggle, as economic reality rapidly sets in. Of all the indexes, the NYA (NYSE) is the most telling, in my view. To that end, I really don't have much to say, other than this is a beautiful bearish formation, with the economic backdrop to support a short-thesis. Bank losses are beyond anything this world has ever seen, credit defaults are skyrocketing (and holding new highs), bankruptcies have surpassed covid levels, crypto fraud is completely out of control, and wars are raging on 3 continents. The only question now is how deep will it go and how quickly will / to what extent will the federal government intervene? Expect a couple years of deterioration to the downside. Good luck and godspeed!
TVC:NYAShort
by ChiefMacro
2
Teva long positionTeva looks like a student who failed an exam and now desperately tries to cover the gaps literally, the gap around 21.4. On the chart we see a clear breakout of the descending channel followed by a neat retest from above, suggesting the stock is ready to get back into a long-term uptrend. Volumes in the 17–17.5 zone act like a safety cushion, preventing the price from dropping too sharply. Technically the next target is gap closure in the 21–22 area, which may unlock the path to higher levels. From the fundamental side, Teva also has some cards to play: the pharmaceutical sector remains in focus due to rising demand for medicines and biotech solutions, and the company has been cleaning up its balance sheet while expanding new business lines. Altogether, both technicals and fundamentals point in the same direction , buyers are not ready to give up just yet.
NYSE:TEVALong
by InvestWorld_777
Reversal At New ATH Points To Next Potential Takeoff For JOBYNYSE:JOBY has been making impressive steps lately with reports coming out Friday, August 15th that the company has achieved a great milestone in being the first to fly a piloted electric vertical takeoff and landing air taxi or eVTOL from one public airport being Marina (OAR) to Monterey (MRY). www.tradingview.com To end last week and start this week we see price on NYSE:JOBY plummeting and this decline has confirmed a very strong reversal pattern, the Head and Shoulders! Now, Price has made a solid breakout of the Neckline or Support of the Pattern so we can suspect a potential pullback to the Neckline for a Retest before moving down further in the coming days. Based off the Potential Extension of a Confirmed Breakout and Validated Retest of a Head and Shoulders Pattern, we can suspect that Price will fall the same length as from the Head to the Neckline, being approx. $4.63, which would land Price not only right in the middle of the Fibonacci Golden Ratio Zone but also a Previous High from June of 2023 @ $11.98! --> This will be the next Buy Opportunity! With NYSE:JOBY expanding by purchasing Blade Air Mobility who operated in lounges and terminals in the US and Europe and plans to deploy commercially in 2026, this could be a great stock to stock up on! www.tradingview.com
NYSE:JOBYLong
by Novi_Fibonacci
Insiders are selling Roblox ! Heres the levels you need to knowIn this video I lay out a solid plan for a move to the downside for Roblox after a 100% move to the upside since April of this year . I demonstrate why I believe we will take a 30% retracement and provide confluent evidence to support this theory. There are some fundamental reasons that I also did include alongside the technical analysis which is not my regular style but important given the context. Tools used in the video 0.382 Fib , Standard Fib pull, Trend based fib and pivots .
NYSE:RBLXShort
by SJTRADESFUTURES
2
U : Long There were both good and bad developments for Unity. While the joint project opportunity with BMW Group is very positive news, Departure of the current CEO was negative news. Technically, it is above the 50 and 200 period moving averages, and the 50 period ema is also above the 200 period ema. A risk/reward ratio of 3.00 can be evaluated, with the Stop-Loss being close to the 200-period ema and the target price being targeted at the large gap closing value.(Small position size) Entry : 24.76 - 24.81 Risk/Reward Ratio : 3.00 Stop-Loss : 22.23 Take Profit Level: 32.54
NYSE:ULong
by Noldo
UNH : Are Bad Days Over ? (Cautious)UNH shares have moved above the 50-period moving average but are trading below the 200-period moving average. For now, since the 200-period moving average is very high, a small trade can be tried by keeping the stop-loss level a little tight. A few weak movements may pull the average down and the price may break the average. Therefore, small position sizes are ideal. NOTE : If we can maintain persistence on 376(Which will take a few days), then we will look at the other gaps. Risk/Reward Ratio : 2.39 Stop-Loss : 274.99 Take- Profit Level : 376.38 Regards.
NYSE:UNHLong
by Noldo
TESLA 400 BY END OF YEAR !! 5 REASONS !!! 1. **Strong Earnings and Revenue Growth** Tesla has a track record of exceeding earnings expectations. If the company reports robust financial results in Q3 and Q4—driven by higher vehicle deliveries and growth in its energy storage business—investors are likely to gain confidence. This could push the stock price upward as Tesla demonstrates its ability to scale profitably. 2. **Advancements in Autonomous Driving** Tesla’s Full Self-Driving (FSD) technology is a game-changer in the making. If Tesla achieves significant progress toward Level 4 or 5 autonomy—where vehicles can operate with little to no human intervention—it could position the company as a leader in transportation innovation. Such a breakthrough would likely excite investors and drive the stock price higher. 3. **Battery Technology Innovation** Tesla is working on developing cheaper, longer-lasting batteries, which could lower production costs and improve profit margins. If the company announces advancements in battery tech—such as improvements from its Battery Day initiatives or new manufacturing processes—it could signal a competitive edge, boosting the stock to $400. 4. **Global Expansion and Production Increases** Tesla’s new Gigafactories in Texas and Berlin are ramping up production, while potential market entries like India loom on the horizon. Increased output and access to new customers signal strong growth potential. If Tesla successfully scales its operations, investors may see this as a reason to push the stock price toward $400. 5. **Favorable Market Trends and Government Policies** The global shift toward sustainable energy and electric vehicles (EVs) is accelerating, supported by government incentives and regulations favoring clean energy. If EV adoption continues to rise and policies provide a tailwind—such as subsidies or stricter emissions standards—Tesla, as an EV leader, could see increased demand and a higher stock valuation. While reaching $400 by year-end is ambitious, Tesla’s strong brand, innovative edge, and leadership under Elon Musk could make it achievable. That said, risks like market volatility and growing competition from other EV makers could pose challenges. If these five factors align, however, Tesla’s stock has a solid shot at hitting that target.
NASDAQ:TSLALong
by NYRUNSGLOBAL
My buy view for Hims & Hers stock. My buy view for Hims & Hers stock. Overall, I believe this asset is still in a bullish direction. I remember hoping into accummulating this stock when it dropped from $64 to $41 at the open of market on 23/6/2025 which I sold off when it hit $50. However, I still hold a strong buy bias with my entry and exit showing on my chart (analysis). Please trade with care as I still look forward to $64 per share for this stock long-term. Please, kindly like, share your thoughts via comment and follow me for more.
NYSE:HIMSLong
by ForexClinik
Analysis on circle using tpo and regular chart longs and shortMust watch video giving 2 really nice Risk reward entries on the Newley listed stock Circle In this video I highlight a region using limited data of where to get filled if you missed the IPO and want to buy some circle . We are currently in a no trade zone for buyers as I anticipate that price will gravitate down to the .786/.886 level over time . In this video I also use the TPO chart "Time price opportunity" and demonstrate what i am looking for from using this type of chart to add to my confluences for a high probability trade . Also identified in the chart is a short trade off of the weekly pivots and the value area high of the range . Thankyou for watching and i welcome any questions
NYSE:CRCL
by SJTRADESFUTURES
5